Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass
- PMID: 35307639
- PMCID: PMC9634875
- DOI: 10.5152/eurasianjmed.2022.20394
Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass
Abstract
Vasoplegia is defined by hypotension and low systemic vascular resistance despite the normal or elevated cardiac index, a complication frequently following cardiac surgery, carrying high morbidity and mortality rate. Vasoplegia is related with a profound systemic inflammatory response and is mainly mediated by cellular hyperpolarization, a relative vasopressin deficiency, and high levels of inducible nitric oxide, following cardiopulmonary bypass. Cardiopulmonary bypass is a distinct precipitant of vasoplegia, generally due to its association with nitric oxide production and severe vasopressin depletion. Postoperative vasoplegia is usually managed with vasopressors, of which catecholamines are the traditional agents of choice. Recent studies promote the use of non-catecholamine vasopressor (vasopressin) in restoring systemic vascular resistance. Alternative agents are also able to restore vascular tone and improve vasoplegia, including methylene blue, angiotensin II, hydroxocobalamin, and ascorbic acid; however, their effect on patient outcomes is still unclear .
Conflict of interest statement
Figures


Similar articles
-
Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy.J Cardiothorac Vasc Anesth. 2018 Apr;32(2):1013-1022. doi: 10.1053/j.jvca.2017.10.032. Epub 2017 Oct 27. J Cardiothorac Vasc Anesth. 2018. PMID: 29223724 Review.
-
Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management.J Card Surg. 2021 Oct;36(10):3749-3760. doi: 10.1111/jocs.15805. Epub 2021 Jul 12. J Card Surg. 2021. PMID: 34251716
-
Methylene Blue for Vasoplegia When on Cardiopulmonary Bypass During Double-Lung Transplantation.A A Case Rep. 2015 Oct 15;5(8):127-30. doi: 10.1213/XAA.0000000000000190. A A Case Rep. 2015. PMID: 26466303
-
Use of Intravenous Hydroxocobalamin without Methylene Blue for Refractory Vasoplegic Syndrome After Cardiopulmonary Bypass.Am J Case Rep. 2021 Jun 18;22:e930890. doi: 10.12659/AJCR.930890. Am J Case Rep. 2021. PMID: 34143764 Free PMC article.
-
Vasoplegia During Cardiopulmonary Bypass: Current Literature and Rescue Therapy Options.J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2766-2775. doi: 10.1053/j.jvca.2019.12.013. Epub 2019 Dec 14. J Cardiothorac Vasc Anesth. 2020. PMID: 31917073 Review.
Cited by
-
Hydroxocobalamin as Rescue Therapy in a Patient With Refractory Amlodipine-Induced Vasoplegia.Cureus. 2023 May 1;15(5):e38400. doi: 10.7759/cureus.38400. eCollection 2023 May. Cureus. 2023. PMID: 37265888 Free PMC article.
-
Hemoadsorption in Complex Cardiac Surgery-A Single Center Experience.J Clin Med. 2022 Nov 27;11(23):7005. doi: 10.3390/jcm11237005. J Clin Med. 2022. PMID: 36498579 Free PMC article.
-
Vasoplegia: A Review.Methodist Debakey Cardiovasc J. 2023 Aug 1;19(4):38-47. doi: 10.14797/mdcvj.1245. eCollection 2023. Methodist Debakey Cardiovasc J. 2023. PMID: 37547893 Free PMC article. Review.
-
Prognostic value of the vasoactive-inotropic score in predicting outcomes following LVAD implantation.JHLT Open. 2025 Apr 24;9:100272. doi: 10.1016/j.jhlto.2025.100272. eCollection 2025 Aug. JHLT Open. 2025. PMID: 40475034 Free PMC article.
-
Severe Refractory Vasoplegic Shock Syndrome after OPCABG Successfully Treated with Hydroxycobalamin: A Case Report and Review of the Literature.J Clin Med. 2023 Dec 28;13(1):169. doi: 10.3390/jcm13010169. J Clin Med. 2023. PMID: 38202178 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources